CoChat

S-1: a promising new oral fluoropyrimidine derivative

Saif, Muhammad Wasif, Syrigos, Kostas N, Katirtzoglou, Nikos A · 2009 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Abstract

The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a wide range of solid tumors, particularly gastric, colorectal, and head and neck cancers. Whilst infusional 5-FU is associated with higher response rates and a favorable safety profile compared with the classical i.v. bolus administration, prolonged infusions can be inconvenient for the patients, and catheter-related problems are common complications. An oral 5-FU formulation would allow for sustained 5-FU plasma concentrations, mimicking the pharmacokinetics (PK) of a continuous infusion with the addition of convenience of administration. The oral administration of 5-FU itself is not feasible owing to the high activity of dihydropyrimidine dehydrogenase (DPD) in the gut wall, which causes rapid metabolism of the drug and results in decreased and erratic absorption of 5-FU and nonlinear PK. To bypass this problem, oral fluoropyrimidine derivatives were developed either in the form of 5-FU prodrugs (i.e., tegafur, doxifluridine or capecitabine), or as enzyme inhibitors (i.e., eniluracil) administered with 5-FU, or as both prodrugs and enzyme inhibitors (i.e., S-1, UFT or BOF-A2). This review focuses on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Phase II trials have demonstrated that S-1, as a single agent, is active for the treatment of gastric, colorectal, head and neck, breast, non-small cell lung, and pancreatic cancers. Phase III trials are currently underway in gastric cancer and these results are awaited to confirm the Phase II findings. Furthermore, the combination of S-1 with cisplatin (CDDP), irinotecan or docetaxel for the treatment of gastric cancer and with CDDP for non-small cell and pancreatic cancer is feasible and active. The activity observed with S-1 in the Phase II studies is at least equivalent to, if not better than, continuous i.v. and bolus 5-FU and the other oral fluoropyrimidines. Thus, we may finally be seeing the realization of oral treatments for the management of various solid tumors and could be on the brink of a new approach to treatment strategies.

Overview

Integrity signals

Registry

Crossref · 10.1517/13543780902729412

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 101 references

Research works printed but not linked: 59

  1. Kubota, 2001, Gan To Kagaku Ryoho, 28, 433
  2. Benson, 1998, Oncology (Williston Park), 12, 28
  3. Houghton, 1979, Cancer Res, 39, 2406
  4. Unemi, 1971, Gan No Rinsho, 17, 731
  5. Lamont, 1999, Clin Cancer Res, 5, 2289
  6. Skipper, 1964, Cancer Chemother Rep, 35, 1
  7. Fraile, 1980, Cancer Res, 40, 2223
  8. Schilsky, 1998, Oncology (Williston Park), 12, 13
  9. Toide, 1977, Gann, 68, 553
  10. Fujii, 1978, Gann, 69, 763
  11. Shirasaka, 2000, Gan To Kagaku Ryoho, 27, 832
  12. Tatsumi, 1987, Jpn J Cancer Res, 78, 748
  13. Shirasaka, 2006, Gan To Kagaku Ryoho, 33, 4
  14. Shirasaka, 1993, Cancer Res, 53, 4004
  15. Kato, 2001, Anticancer Res, 21, 1705
  16. Cao, 1999, Clin Cancer Res, 5, 267
  17. Shirasaka, 1996, Cancer Res, 56, 2602
  18. Shirasaka, 1993, Proc Int Congr Chemother, 18, 927
  19. Fukushima, 1998, Int J Oncol, 13, 693
  20. Shirasaka, 1998, Gan To Kagaku Ryoho, 25, 371
  21. Taguchi, 1997, Gan To Kagaku Ryoho, 24, 2253
  22. Hirata, 1999, Clin Cancer Res, 5, 2000
  23. Hoff, 1999, Proc Am Soc Clin Oncol, 18, 665
  24. Hoff, 2003, Clin Cancer Res, 9, 134
  25. Tagishi, 1996, Proc Am Soc Clin Oncol, 15, 151
  26. Taguchi, 1998, Gan To Kagaku Ryoho, 25, 1035
  27. Sano, 2000, Proc Am Soc Clin Oncol, 19, 404
  28. 10.1054/bjoc.2001.2031 · doi:10.1054/bjoc.2001.2031 · Paper page
  29. Fujii, 1996, Proc Am Soc Clin Oncol, 15, 894
  30. Inuyama, 1998, Gan To Kagaku Ryoho, 25, 1151
  31. Inuyama, 2001, Gan To Kagaku Ryoho, 28, 1381
  32. Okada, 2002, Proc Am Soc Clin Oncol, 21, 171a
  33. Hayashi, 2002, Oncol Rep, 9, 1355
  34. Sawada, 2002, Proc Am Soc Clin Oncol, 21, 102b
  35. Horikoshi, 1996, Proc Am Soc Clin Oncol, 15, 466
  36. Miyamoto, 2000, Int J Oncol, 17, 653
  37. Yoshida, 2001, Gan To Kagaku Ryoho, 28, 1403
  38. Inaba, 2002, Gan To Kagaku Ryoho, 29, 239
  39. Osugi, 2002, Oncol Rep, 9, 811
  40. Moriwaki, 2003, Gan To Kagaku Ryoho, 30, 489
  41. Fujitani, 2003, Hepato-gastroenterology, 50, 889
  42. Kinoshita, 2005, Prog Proc Am Soc Clin Oncol, 23, 313
  43. Scanlon, 1983, Cancer Res, 43, 4211
  44. Shirasaka, 1999, Gan To Kagaku Ryoho, 26, 456
  45. Mizutani, 1999, Oncol Rep, 6, 979
  46. Nishiyama, 1999, Clin Cancer Res, 5, 2620
  47. Tsuji, 1999, Gan To Kagaku Ryoho, 26, 326
  48. Ohtsu, 2001, Proc Am Soc Clin Oncol, 20, 165a
  49. Kamata, 2001, Gan To Kagaku Ryoho, 28, 1419
  50. Tsujitani, 2003, Proc Am Soc Clin Oncol, 22, 1358
  51. Narahara, 2002, Proc Am Soc Clin Oncol, 21, 170a
  52. Komatsu, 2002, Proc Am Soc Clin Oncol, 21, 171a
  53. Yamashita, 2003, Proc Am Soc Clin Oncol, 22, 1428
  54. Yamada, 2003, Proc Am Soc Clin Oncol, 22, 1314
  55. Komatsu, 2003, Proc Am Soc Clin Oncol, 22, 1282
  56. Rino, 2006, Anticancer Res, 26, 1455
  57. Yoshida, 2003, Proc Am Soc Clin Oncol, 22, 1292
  58. Saif, 2008, JOP, 9, 226
  59. Kouwaki, 1998, Clin Cancer Res, 4, 2999

Cited by

See all 104

Metadata

Authors
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Yale University (US)
Venue
Expert Opinion on Investigational Drugs
Published
2009-03
Volume
18
Issue
3
Pages
335-348
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2168388707
Cited by
101
References
100
Citations by year
2026: 4 · 2025: 7 · 2024: 10 · 2023: 1 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 7 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 10
FWCI
4.14
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
S-1, oral fluoropyrimidine, tegafur, 5-fluorouracil prodrug, dihydropyrimidine dehydrogenase inhibition, potassium oxonate, gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, combination chemotherapy
MeSH terms
Administration, Oral, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Drug Combinations, Drug Evaluation, Preclinical, Tegafur, Humans, Neoplasms, Oxonic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: S-1: a promising new oral fluoropyrimidine derivative. https://app.cochat.ai/papers/10.1517/13543780902729412
The paper
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009). S-1: a promising new oral fluoropyrimidine derivative. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780902729412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.